TheraGenetics Lands $6M in Series A VC Funds | GenomeWeb
NEW YORK (GenomeWeb News) — TheraGenetics has raised $6 million in a Series A round of venture capital financing, the company said Tuesday.  
 
TheraGenetics CEO Richard Kivel said the funds will help expand the company’s IP position and will speed its diagnostic development.
 
The company has developed a series of diagnostics for disorders affecting the central nervous system such as schizophrenia, Alzheimer’s disease, and mood disorders.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.